Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 plus rituximab versus R-GemOx or R-ICE in relapsed/refractory diffuse large B-cell lymphoma
CTR20244220Phase 3Active
- Sponsor
- BeBetter Med
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ifupinostat, rituximab, gemcitabine, oxaliplatin, ifosfamide in diffuse large B-cell lymphoma (DLBCL), sponsored by BeBetter Med. Started Jan 2025; status: active.
02
Drugs
ifupinostatrituximabgemcitabineoxaliplatinifosfamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20244220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244220.